🔎 Trials Near Me

Home › Pancreatic Cancer › NCT04970056

Pancreatic Cancer Early Detection Consortium

RecruitingObservational studyHealthy volunteers welcome

Who can join

Ages 18 to 90 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

Individuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:

Cohort 1

Individuals without history of PDAC meeting any of the following criteria:

1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+

Cohort 2

Individuals without history of PDAC meeting any of the following criteria:

1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member

Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)

Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.

Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.

Cohort 6a

Individuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:

1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11

Cohort 6b

Individuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:

1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
3. Diagnosed ≤ age 45

Cohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.

Cohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.

Cyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)

Exclusion Criteria:

* Individuals not meeting the criteria above.

About the study

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Sponsor: Arbor Research Collaborative for Health · Participants: 20,000 · Started: Sep 18, 2020

Contact the study team

Official record on ClinicalTrials.gov — NCT04970056

Locations in the U.S.

ArizonaMayo Clinic Arizona, Phoenix (Not yet recruiting)
Honor Health Research Institute, Scottsdale
CaliforniaProvidence Health and Services, Burbank
City of Hope, Duarte
UC San Diego Moores Cancer Center, La Jolla
Cedars-Sinai Medical Center, Los Angeles
UCLA Health, Los Angeles
Hoag, Newport Beach
UC Irvine Health, Orange
UC Davis, Sacramento
University of California, San Francisco (UCSF), San Francisco
ConnecticutYale University, New Haven
FloridaMayo Clinic Jacksonville, Jacksonville
University of Miami, Miami
Moffitt Cancer Center, Tampa
GeorgiaEmory University Hospital, Atlanta
IllinoisIllinois CancerCare, Bloomington
University of Chicago Medicine, Chicago
NorthShore University HealthSystem, Evanston
KansasUniversity of Kansas Medical Center, Kansas City
MassachusettsMassachusetts General Hospital, Boston
Umass Memorial Medical Center, Worcester
MichiganUniversity of Michigan, Ann Arbor
Beaumont/Corewell Health, Royal Oak
NebraskaUniversity of Nebraska Medical Center, Omaha
New JerseyHackensack Meridian Health, Hackensack
New YorkColumbia University Irving Medical Center, New York
Icahn School of Medicine At Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York (Not yet recruiting)
University of Rochester Medical Center, Rochester
White Plains Hospital, White Plains
OhioThe Ohio State University, Columbus
OregonOregon Health & Science University, Portland
PennsylvaniaFox Chase Cancer Center, Philadelphia
University of Pennsylvania, Philadelphia
University of Pittsburgh Medical Center (Upmc), Pittsburgh
TennesseeUniversity of Tennessee Graduate School of Medicine, Knoxville
UtahHuntsman Cancer Institute, Salt Lake City
VirginiaUniversity of Virginia, Charlottesville
Inova Schar Cancer Institute, Fairfax
VCU Massey Comprehensive Cancer Center, Richmond
WashingtonUniversity of Washington, Seattle

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.